Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7841675 | 0.94 | ELANE (0.48) | ELANECTRB1 | |
| SCHEMBL6802037 | 0.93 | ELANE (0.46) | ELANECTRB1LMNA | |
| SCHEMBL7449581 | 0.92 | ELANE (0.46) | ELANECTRB1KLKB1LMNATP53 | |
| SCHEMBL6498129 | 0.91 | ELANE (0.44) | ELANECTRB1 | |
| SCHEMBL6805848 | 0.90 | ELANE (0.44) | ELANECTRB1LMNA | |
| SCHEMBL7844661 | 0.90 | CTRB1 (0.49) | ELANECTRB1LMNA | |
| SCHEMBL6803240 | 0.89 | ELANE (0.43) | ELANECTRB1LMNA | |
| SCHEMBL7447074 | 0.89 | ELANE (0.45) | ELANECTRB1LMNA | |
| SCHEMBL6505448 | 0.88 | ELANE (0.40) | ELANEKLKB1LMNA | |
| SCHEMBL6497577 | 0.88 | ELANE (0.40) | ELANEKLKB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | claimed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | claimed |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1122245-A2 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. Searle & Co. (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, ACE2 | ELANE 1199/4885CTRB1 1716/4885KLKB1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.